Synaptic Action of Anandamide and Related Substances in Mammalian Brain

Total Page:16

File Type:pdf, Size:1020Kb

Synaptic Action of Anandamide and Related Substances in Mammalian Brain SYNAPTIC ACTION OF ANANDAMIDE AND RELATED SUBSTANCES IN MAMMALIAN BRAIN by Chengyong Liao M.Sc., Sichuan University, 1991 B.Sc., Sichuan University, 1984 THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Inthe Department of Biological Sciences © Chengyong Liao 2007 SIMON FRASER UNIVERSITY 2007 All rights reserved. This work may not be reproduced in whole or in part, by photocopy or other means, without permission ofthe author. APPROVAL Name: Chengyong Liao Degree: Doctor of Philosophy Title of Thesis: Synaptic Actions of Anandamide and Related Substances in Mammalian Brain Examining Committee: Chair: Dr. Z. Punja Professor ofDepartment ofBiological Sciences, SFU. Dr. R. A. Nicholson Senior Supervisor Associate Professor ofDepartment ofBiological Sciences, SFU. Dr. C. J. Kennedy, Supervisor Associate Professor of Department ofBiological Sciences, SFU Dr. F. C. P. Law, Supervisor Professor ofDepartment ofBiological Sciences, SFU Dr. M. A. Silverman Public Examiner Associate Professor ofDepartment ofBiological Sciences, SFU Dr. J. Church External Examiner Professor ofDepartment ofCellular and Physiological Sciences, UBC Date Defended/Approved: 11 SIMON FRASER UNIVERSITY LIBRARY Declaration of Partial Copyright Licence The author, whose copyright is declared on the title page of this work, has granted to Simon Fraser University the right to lend this thesis, project or extended essay to users of the Simon Fraser University Library, and to make partial or single copies only for such users or in response to a request from the library of any other university, or other educational institution, on its own behalf or for one of its users. The author has further granted permission to Simon Fraser University to keep or make a digital copy for use in its circulating collection (currently available to the public at the "Institutional Repository" link of the SFU Library website <www.lib.sfu.ca> at: <http://ir.lib.sfu.ca/handle/1892/112>) and, without changing the content, to translate the thesis/project or extended essays, if technically possible, to any medium or format for the purpose of preservation of the digital work. The author has further agreed that permission for multiple copying of this work for scholarly purposes may be granted by either the author or the Dean of Graduate Studies. It is understood that copying or publication of this work for financial gain shall not be allowed without the author's written permission. Permission for public performance, or limited permission for private scholarly use, of any multimedia materials forming part of this work, may have been granted by the author. This information may be found on the separately catalogued multimedia material and in the signed Partial Copyright Licence. While licensing SFU to permit the above uses, the author retains copyright in the thesis, project or extended essays, including the right to change the work for subsequent purposes, including editing and publishing the work in whole or in part, and licensing other parties, as the author may desire. The original Partial Copyright Licence attesting to these terms, and signed by this author, may be found in the original bound copy of this work, retained in the Simon Fraser University Archive. Simon Fraser University Library Burnaby, BC,Canada Revised: Summer 2007 STATEMENT OF ETHICS APPROVAL The author, whose name appears on the title page of this work, has obtained, for the research described inthis work, either: (a) Human research ethics approval from the Simon Fraser University Office of Research Ethics, or (b) Advance approval ofthe animal care protocol from the University Animal Care Committee ofSimon Fraser University; orhas conducted the research (c) as a co-investigator, in a research project approved in advance, or (d) as a member of a course approved in advance for minimal risk human research, by the Office ofResearch Ethics. A copy of the approval letter has been filed at the Theses Office of the University Library atthe time ofsubmission ofthis thesis orproject. The original application for approval and letter of approval are filed with the relevant offices. Inquiries may be directed tothose authorities. Simon Fraser University Library Burnaby, BC, Canada ABSTRACT Anandamide and the synthetic cannabimimetic drugs AM 404 and WIN 55,212-2 were found to inhibit the binding of CH]batrachotoxinin A 20-a.-benzoate (BTX) to voltage-gated sodium channels (VGSCs) and also to depress VGSC-dependent release of GABA and L-glutamic acid. These effects occur independently of CB-l receptor activation since they were not attenuated by AM251 at concentrations known to antagonize CB-l receptors, although at higher concentrations AM251 inhibited VGSCs also. These results suggest that anandamide and endocannabimimetics have the ability to depress synaptic transmission by reducing the capacity of VGSCs to support action potentials. In other experiments, I observed that anandamide is synthesized by both resting and depolarized synaptoneurosomes, however, data from filtration and superfusion experiments failed to support the hypothesis that depolarization activates the release of anandamide from these synaptic preparations, even though substantial quantities of anandamide were clearly present in the intracellular compartments. In these investigations, I unexpectedly found that CH]ethanolamine (a potential precursor of anandamide) is accumulated by synaptosomes and synaptoneurosomes during extended incubation and released (as CH]ethanolamine) in a calcium-dependent fashion during a depolarizing challenge with 30 mM KCl. Ethanolamine also stimulates the release of the pH fluoroprobe acridine orange (AO) from synaptosomes and decreases AO release when synaptosomes are depolarized with KCl. However, ethanolamine and other amino alcohols (methylethanolamine and dimethylethanolamine) stimulate resting and KCI- 111 evoked release of eH]-D-aspartate from synaptosomes. All amino alcohols rapidly access synaptic vesicles where they sequester protons, thus accounting for AO efflux. Proton sequestration by amino alcohols increases the AIP-dependent transvesicular membrane potential which in tum enhances D-aspartate uptake into synaptic vesicles. My data suggest a potential role for ethanolamine and related amino alcohols in the regulation of synaptic vesicle filling and release of amino acid neurotransmitters. Depolarization evoked release of ethanolamine from synaptosomes supports the idea that this amino alcohol may also have an important postsynaptic role. Keywords: anandamide; cannabinoids; sodium channels; synaptic vesicles; mammalian brain. IV DEDICATION ~~~~~~~*~.W~~~*~~~~.~5o .OO~~~T~~ffim~~, ~*~~o Inmemory ofmy mom and thanks to my father for bringing me upwith love and support. Thanks also to my wife for always supporting me in hard and happy times. v ACKNOWLEDGEMENTS The thesis is a product of many people's support. First and foremost, I thank my senior supervisor Dr. Nicholson for giving me the opportunity to work in his lab. He gave me direct instruction, contributed great ideas, and provided an enjoyable and encouraging environment in which I could display my creation at my best. I appreciate him giving me support throughout my graduate studies. When needed, I always got his timely and effective help. It was great to have a lot of discussion about the project and related scientific issues with him. I enriched my background in related fields. I was fortunate to be his graduate student. I especially thank my supervisory committee members Dr. Law and Dr. Kennedy for their enormous help and direction at each stage of my research. I learned a lot from Dr. Law for example, chromatography theory relating to HPLC analysis and the way to effectively deliver an oral presentation of my research. I will never forget Dr. Kennedy who provided me with the necessary instruments and apparatus for my research and gave me his encouragement in the hard times of my study. I especially thank my good friend Jian Zheng who introduced me to Dr. Nicholson's lab and helped me to master many important skills for the research ahead. I would like to thank Yanshen Deng for mentoring me and making me familiar with SFU facilities and giving me guidance in my work. I would like to thank my colleague Yin Duan, who assisted me in many aspects such as preparing mitochondria, and other lab work, especially when it was difficult to balance my lab work and taking care of my baby. I thank QiangTu Zhang and Dan Sit VI who assisted me in optimizing my HPLC analysis. I will never forget the help and assistance provided by so many people at SFU such as Xui He, Ying Zhen, Guanghua Gao, Laurance David and Sudip Ghose. I would like especially to thank a very special person who gave me great support in my study, my wife Chaoli Wang. She always stands behind me and always ensured that I had a quiet environment for my study at home. I will never forget the support from my parents. So that I was not distracted in my research, my mom did not tell me about her serious illness before she passed away. I always got strong support and encouragement from my family and Chaoli's family. Without their support, it would have been impossible for me to complete my Ph.D. study. I sincerely thank them. vii TABLE OF CONTENTS Approval ii Abstract iii Dedication v Acknowledgements vi Table of Contents viii List ofFigures xii List of Tables xv Glossary xvi Chapter 1 Introduction 1 1.1 The discovery ofthe endocannabinoid system in mammals 1 1.2 The synthesis
Recommended publications
  • Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic
    ANTICANCER RESEARCH 37 : 161-168 (2017) doi:10.21873/anticanres.11301 Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells I-TSANG CHIANG 1,2,3* , WEI-TING CHEN 4* , CHIH-WEI TSENG 5, YEN-CHUNG CHEN 2,6 , YU-CHENG KUO 7, BI-JHIH CHEN 8, MAO-CHI WENG 9, HWAI-JENG LIN 10,11# and WEI-SHU WANG 2,12,13# Departments of 1Radiation Oncology, 6Pathology, and 13 Medicine, and 2Cancer Medical Care Center, National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.; 3Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; 4Department of Psychiatry, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.; 5Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan, R.O.C.; 7Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; 8Department of Laboratory Medicine, Changhua Christian Hospital, Changhua Christian Medical Foundation, Changhua, Taiwan, R.O.C.; 9Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C.; 10 Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.; 11 Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C.; 12 National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. Abstract. The aim of the present study was to investigate the (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP), antitumor effect and mechanism of action of hyperforin in myeloid cell leukemia 1(MCL1), and cyclin-D1] were hepatocellular carcinoma (HCC) SK-Hep1 cells in vitro.
    [Show full text]
  • WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US).
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Assessment Report on Hypericum Perforatum L., Herba
    European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101303/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON HYPERICUM PERFORATUM L., HERBA 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS I. REGULATORY STATUS OVERVIEW...................................................................................4 II. ASSESSMENT REPORT............................................................................................................5 II.1 INTRODUCTION..........................................................................................................................6 II.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations thereof 6 II.1.1.1 Herbal substance:........................................................................................................ 6 II.1.1.2 Herbal preparation(s): ................................................................................................ 7 II.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)........................... 9 Not applicable. ................................................................................................................................9 II.1.1.4 Vitamin(s) ...................................................................................................................
    [Show full text]
  • Serotonin Syndrome How to Avoid, Identify, &
    Serotonin syndrome How to avoid, identify, & As the list of serotonergic agents grows, recognizing hyperthermic states and potentially dangerous drug combinations is critical to our patients’ safety. 14 Current VOL. 2, NO. 5 / MAY 2003 p SYCHIATRY Current p SYCHIATRY treat dangerous drug interactions Harvey Sternbach, MD Clinical professor of psychiatry UCLA Neuropsychiatric Institute Los Angeles, CA romptly identifying serotonin syn- drome and acting decisively can keep side effects at the mild end of the spec- Ptrum. Symptoms of this potentially dangerous syndrome range from minimal in patients starting selective serotonin reuptake inhibitors (SSRIs) to fatal in those combining monoamine oxidase inhibitors (MAOIs) with serotonergic agents. This article presents the latest evidence on how to: • reduce the risk of serotonin syndrome • recognize its symptoms • and treat patients with mild to life- threatening symptoms. WHAT IS SEROTONIN SYNDROME? Serotonin syndrome is characterized by changes in autonomic, neuromotor, and cognitive-behav- ioral function (Table 1) triggered by increased serotonergic stimulation. It typically results from pharmacodynamic and/or pharmacokinetic in- teractions between drugs that increase serotonin activity.1,2 continued VOL. 2, NO. 5 / MAY 2003 15 Serotonin Table 1 activity or reduced ability to How to recognize serotonin syndrome secrete endothelium-derived nitric oxide may diminish the System Clinical signs and symptoms ability to metabolize serotonin.2 Autonomic Diaphoresis, hyperthermia, hypertension, tachycardia, pupillary dilatation, nausea, POTENTIALLY DANGEROUS diarrhea, shivering COMBINATIONS Neuromotor Hyperreflexia, myoclonus, restlessness, MAOIs. Serotonin syndrome tremor, incoordination, rigidity, clonus, has been reported as a result of teeth chattering, trismus, seizures interactions between MAOIs— Cognitive-behavioral Confusion, agitation, anxiety, hypomania, including selegiline and insomnia, hallucinations, headache reversible MAO-A inhibitors (RIMAs)—and various sero- tonergic compounds.
    [Show full text]
  • WO 2018/130682 Al 19 July 2018 (19.07.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/130682 Al 19 July 2018 (19.07.2018) W !P O PCT (51) International Patent Classification: Published: C12P 7/22 (2006.0 1) C12P 17/06 (2006.0 1) — with international search report (Art. 21(3)) (21) International Application Number: PCT/EP20 18/050860 (22) International Filing Date: 15 January 2018 (15.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/446,429 14 January 2017 (14.01.2017) US 62/524,239 23 June 2017 (23.06.2017) us 62/546,372 16 August 2017 (16.08.2017) us (71) Applicant: HERBOLEA S.R.L. [IT/IT]; Piazza Fra Giro- lamo Savonarola, 10, 50132 FIRENZE (IT). (72) Inventor: VENTURINI DEL GRECO, Giovanni; Via Carducci, 16, 50121 FIRENZE (IT). (74) Agent: ZACCARO, Elisabetta et al; NOTARBARTOLO & GERVASI S.P.A., Corso di Porta Vittoria 9, 20122 Mi- lano (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW,KZ, LA, LC, LK, LR, LS, LU, LY,MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Transient Receptor Potential Channels As Drug Targets: from the Science of Basic Research to the Art of Medicine
    1521-0081/66/3/676–814$25.00 http://dx.doi.org/10.1124/pr.113.008268 PHARMACOLOGICAL REVIEWS Pharmacol Rev 66:676–814, July 2014 Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: DAVID R. SIBLEY Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine Bernd Nilius and Arpad Szallasi KU Leuven, Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research, Campus Gasthuisberg, Leuven, Belgium (B.N.); and Department of Pathology, Monmouth Medical Center, Long Branch, New Jersey (A.S.) Abstract. ....................................................................................679 I. Transient Receptor Potential Channels: A Brief Introduction . ...............................679 A. Canonical Transient Receptor Potential Subfamily . .....................................682 B. Vanilloid Transient Receptor Potential Subfamily . .....................................686 C. Melastatin Transient Receptor Potential Subfamily . .....................................696 Downloaded from D. Ankyrin Transient Receptor Potential Subfamily .........................................700 E. Mucolipin Transient Receptor Potential Subfamily . .....................................702 F. Polycystic Transient Receptor Potential Subfamily . .....................................703 II. Transient Receptor Potential Channels: Hereditary Diseases (Transient Receptor Potential Channelopathies). ......................................................704
    [Show full text]
  • WO 2018/152334 Al 23 August 2018 (23.08.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/152334 Al 23 August 2018 (23.08.2018) W !P O PCT (51) International Patent Classification: (US). YUCEL, Tuna; 28 Monmouth Avenue, Medford, A61K 9/107 (2006.01) A61K 31/352 (2006.01) MA 02155 (US). BOYLAN, Nicholas, J.; 215 Green A61K 47/26 (2006.01) A61K 9/48 (2006.01) Street, Boylston, MA 01505 (US). A61K 47/14 (2006.01) A61K 9/00 (2006.01) (74) Agent: EISENSCHENK, Frank, C. et al; Saliwanchik, A61K 31/05 (2006 .01) A61P 25/06 (2006 .0 1) Lloyd & Eisenschenk, P.O. Box 142950, Gainesville, FL (21) International Application Number: 32614-2950 (US). PCT/US2018/018382 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 15 February 2018 (15.02.2018) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/459,086 15 February 2017 (15.02.2017) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/546,149 16 August 2017 (16.08.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, (71) Applicant: MOLECULAR INFUSIONS, LLC [US/US]; TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Elucidation of Anti-Inflammatory Constituents in Hypericum
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2008 Elucidation of anti-inflammatory constituents in Hypericum perforatum extracts and delineation of mechanisms of anti-inflammatory activity in RAW 264.7 mouse macrophages Kimberly Dawn Petry Hammer Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Genetics and Genomics Commons Recommended Citation Hammer, Kimberly Dawn Petry, "Elucidation of anti-inflammatory constituents in Hypericum perforatum extracts and delineation of mechanisms of anti-inflammatory activity in RAW 264.7 mouse macrophages" (2008). Retrospective Theses and Dissertations. 15774. https://lib.dr.iastate.edu/rtd/15774 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Elucidation of anti-inflammatory constituents in Hypericum perforatum extracts and delineation of mechanisms of anti-inflammatory activity in RAW 264.7 mouse macrophages by Kimberly Dawn Petry Hammer A dissertation submitted to the graduate faculty in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Genetics Program of Study Committee: Diane Birt, Major Professor Jeff Essner Marian Kohut Chris Tuggle Michael Wannemuehler Iowa State University Ames, Iowa 2008 Copyright © Kimberly Dawn Petry Hammer, 2008. All rights reserved. 3337385 3337385 2009 ii TABLE OF CONTENTS ACKNOWLEDGEMENTS vi ABBREVIATIONS vii LIST OF TABLES ix LIST OF FIGURES x ABSTRACT xi CHAPTER 1.
    [Show full text]
  • Subject Index Volume 23 Number S2
    SUBJECT INDEX VOLUME 23 NUMBER S2 A B Cigarette smoking, S150 Circadian salivary cortisol levels, S105 Abnormal neuroendocrine, S97 B12 vitamin, S140 Circannual melatonin, S108 Abstinent male alcoholics, S156 Beclomethasone-induced vasoconstriction Circuitry pharmacotherapy, S73–S75 Academia, S10 (BIV), S121 Clinical diagnosis, S115 Academically-striving countries, S59 Bed nucleus of the stria terminals, S111 Clinical Global Impression Scale, S116 ACE gene, S130 Behavior problems, S100 Clinical trials, S43 ACE I/D polymorphism, S106 Behavioral effects of NK1, S23 Clobazam, S3 ACTH secretion, S29 Behavioral endocrine responses, S119 Clonidine administration, S132, S139 Acute adolescent mania, S124 Benign intracranial hypertension, S136 Clorniphene, S78 Acute major depressive disorder, S113 Benzodiazepine withdrawal syndrome, Clozapine, S54, S116, S123, S135 Acute schizophrenia, S122 S124 Cocaine, S17, S46, S133 Addiction, S17, S102 Benzodiazapines, S56 Cognition, S51, S79, S92–S94 Administrative arrangements, S9 Benzothiophenes, S79 Cognitive aging, S94 Adolescent, S82 Bilateral grand mal seizure, S91 Cognitive dysfunction, S128 Adrenal hyperplasia, S60 Biochemical markers, S110 Cognitive functioning, S8 Adrenal insufficiency, S48 Biogenic amine systems, S43 Cognitive therapeutic considerations, S99 Adrenalectomy treatment, S145 Biological Psychiatry, S35 Collaboration, S58 ␤-, ␣2-adrenergic receptors, S3 Biosynthesis, S70 Collegium International A2-adrenoceptor supersensibility, S139 Bipolar adolescents, S124 NeuroPsychopharmacologicum,
    [Show full text]